TLDRSELLAS Life Sciences (SLS) stock jumped more than 200% on Tuesday after positive Phase 3 REGAL results.Its cancer vaccine GPS cut the risk of death by 41% in acute myeloid leukemia patients.Median survival was 24.0 months with GPS versus 14.7 months for the control group.The company plans to meet the FDA and file for approval in the first half of 2027.Maxim’s $30 price target now sits much closer to the stock price.SELLAS Life Sciences (SLS) stock jumped more than 200% on Tuesday. The move came after the company reported positive Phase 3 results for its leukemia vaccine.SELLAS Life Sciences Group, Inc., SLSOne early report put the gain at 240% at its peak. Buyers clearly wasted no time.What the REGAL Trial ShowedThe trial tested galinpepimut-S, known as GPS, in acute myeloid leukemia (AML). It met its main goal of overall survival.$SLS +300% (Market cap: ~$6B)Sellas Life Sciences' experimental cancer vaccine extended survival in a pivotal Phase 3 leukemia trial, meeting its primary endpoint.Its vaccine, galinpepimut-S (GPS), reduced the risk of death by 41% compared with the best available treatment in… pic.twitter.com/ApAngqbE9U— Wall St Engine (@wallstengine) November 17, 2026Patients on GPS had a 41% lower risk of death than those on the best available treatment. The hazard ratio was 0.59, and the two-sided p-value was 0.035.Median survival reached 24.0 months with GPS. The control group reached 14.7 months.The analysis ran after 80 events, as the trial plan required. That timing was set in advance.Everyone in the study had reached a second or later complete remission. They also could not have a stem cell transplant, or were not eligible for one.GPS was given alone as maintenance therapy. Its safety profile matched earlier experience, with no new safety signals.Most side effects were mild to moderate. The most common were reactions at the injection site.What Comes Next for SELLASSELLAS plans to meet with the FDA to discuss a faster filing path. It is also preparing a Biologics License Application for the first half of 2027.More detailed trial data is expected at an upcoming medical conference. The company has not been tied to a date in the reports.A second leukemia drug is also moving along. Tambiciclib, or SLS009, is a CDK9 inhibitor in Phase 2 testing.Forty patients have enrolled in its study of newly diagnosed AML. Early findings are expected before year-end.More SLS009 data is headed to the American Society of Hematology meeting in December. Earlier work in relapsed or resistant AML showed response rates of 54% in monocytic AML and 57% in patients with TP53 mutations.SELLAS ended September with $134.7 million in cash and equivalents. Its third-quarter net loss was $10.1 million, up from $6.8 million a year earlier.Maxim analyst Jason McCarthy rates the stock a Buy with a $30 price target. He models GPS revenue starting in 2027 and SLS009 in first-line AML in 2029.Tuesday’s rally has pushed the stock much closer to that target.The post SELLAS Life Sciences (SLS) Stock Surges Over 200% After Phase 3 Leukemia Vaccine Win appeared first on Blockonomi.